Thanks Capt. That sounds logical but I thought I recalled prior posts stating that Hikma would be held to pay for all. Certainly it would seem that Amarin is in a good position against Hikma as they did market for the CVD space. Whatever % they have of the generics 47% of the CVD indication is still a nice amount for damages. And if they can be held to pay treble damages that would be nice sum.
Market Data 
Markets 
AI
